TORONTO and BOSTON, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT; OTCQB: COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that it has entered into a research collaboration with St. Vincent’s University Hospital in Dublin, Ireland to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer.
“Cotinga is committed to the development of therapies for a wide range of cancers, and our collaboration with St. Vincent’s University Hospital represents an important step towards realizing the full potential of our lead compound, COTI-2,” said Dr. Richard Ho, M.D., Ph.D., Chief Scientific Officer. “Throughout this year we presented preclinical and early clinical results that support COTI-2 as a possible combination therapy, and this partnership with St. Vincent’s will allow us to further explore how COTI-2 may work alongside the standard of care in cancers with severe unmet medical need.”
The Phase 1 study will aim to evaluate COTI-2 in combination with eribulin in the second or subsequent line therapy of patients with triple negative metastatic breast cancer. The primary objectives of the study will be to determine the optimal tolerated dose of COTI-2 that can be added to standard dose eribulin in the second or subsequent line treatment of metastatic breast cancer, and to assess the safety and tolerability of COTI-2 when administered with eribulin.
“Triple-negative metastatic breast cancer is a serious and difficult-to-treat disease that tends to be more aggressive than other types of breast cancer,” said Professor John Crown, M.D., M.B.A., consultant medical oncologist at St. Vincent’s University Hospital. “Our research demonstrates that the p53 gene is mutated in approximately 80% of triple-negative tumors, and suggests that mutant p53 has potential as a therapeutic target. We are encouraged by early data from COTI-2, which targets mutant p53, and having seen synergy in our own preclinical testing of COTI-2 and eribulin, we look forward to evaluating the compound in combination with standard of care for patients with triple negative metastatic breast cancer.”
About Cotinga Pharmaceuticals Inc.
Cotinga Pharmaceuticals is a clinical-stage pharmaceutical company that uses proprietary artificial intelligence technologies to pursue a targeted and transformational approach to treating cancer and other unmet medical needs. Cotinga’s CHEMSAS® technology is intended to accelerate the discovery and development of novel drug therapies, allowing the Company to build a pipeline of potential drug candidates faster and with a higher probability of success than traditional methods.
The Company’s lead compound, COTI‐2, has a novel p53‐dependent mechanism of action with selective and potent anti‐cancer activity. P53 mutations occur in over 50% of all cancers. COTI‐2 is initially being evaluated in combination with various standard of care chemotherapy regimens for the treatment of a wide spectrum of cancers in a Phase 1b/2a clinical trial at the MD Anderson Cancer Center at the University of Texas and the Lurie Cancer Center at Northwestern University and a Phase 1 trial at St. Vincent’s University Hospital. The Company has secured orphan drug status in the United States for COTI‐2 for the treatment of ovarian cancer. Preclinical data suggests that COTI-2 could dramatically improve the treatment of cancers with mutations in the p53 gene.
The Company’s second lead compound, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS function. KRAS mutations occur in up to 30% of all cancers and represent a tremendous unmet clinical need and a desirable drug target. COTI-219 is undergoing IND-enabling studies to support a regulatory submission.
Follow @CotingaPharma on Twitter at http://twitter.com/CotingaPharma.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Notice to Readers:
Information contained in this press release may contain certain statements which constitute “forward-looking statements” as such term is defined under applicable securities laws. Forward‐looking statements by their nature are not guarantees of future performance and are based upon management’s current expectations, estimates, projections and assumptions. Cotinga operates in a highly competitive environment that involves significant risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward‐looking statements. Management of Cotinga considers the assumptions on which these forward‐looking statements are based to be reasonable, but as a result of the many risk factors, cautions the reader that actual results could differ materially from those expressed or implied in these forward-looking statements. Information in this press release should be considered accurate only as of the date of the release and may be superseded by more recent information disclosed in later press releases, filings with the securities regulatory authorities or otherwise. Except as required by law, Cotinga assumes no obligation to update forward-looking statements should circumstances or management's expectations, estimates, projections and assumptions change.